HBOT Conversations:
Dr. Hemal Mehta & Fasting (Part 2)
Dr. Hemal Mehta, MD is a Medical Director and an Independent Medical Examiner who focuses on pain management through a Regenerative medicine approach. Dr. Mehta is Board Certified in Physical Medicine and Pain Management. He received his Doctor of Medicine Degree from Ross University School of Medicine and completed his residency at East Carolina. He is the Medical Director of Vibrant Health of North Carolina, Tennessee Integrative Pain Institute, and TN Integrative Healthcare: Musculoskeletal and Regenerative Center; additionally, Dr. Mehta is the attending physician at Nashville Regenerative Orthopedics. Dr. Mehta is the 2013 recipient of the Inaugural Patient Appreciation Award at Nashville Academy of Medicine, and the 2004 Research Resident of the Year for East Carolina University. Dr. Mehta has extensive experience with stem cell proliferation, and angiogenesis. He has incorporated Ozone Injection Therapy, PRP (Platelet-Rich Plasma) Injections, Hyperbaric Oxygen Therapy and Regenerative Matrix and Regenerative Medicine Procedures – to name a few – into his integrative wellness & longevity medical practices.
Watch the Podcast
di Girolamo & Dr. Mehta examine the use of Vitamin C IV therapy for cancer, and how the combination of Vitamin C IV therapy, fasting and oxygen therapy – especially in the form of Hyperbaric Oxygen Therapy – has been known to put patients in remission and completely eliminate some very serious cancers. Dr. Mehta describes Hyperbaric Oxygen as a “game changer” when adding it into a cancer treatment protocol. He explains that as doctors they are trained to look at chemotherapy first to treat cancer, but there are many holistic ways to help a cancer patient shrink the tumors, stop the spread and live a longer life. He agrees that HBOT would be a great option to help cancer patients on their healing journey.
Diet is another holistic way to treat cancer. A water fast that puts the body in a ketogenic state, or a ketogenic organic diet are all ranked high as ideal ways to use alternative, natural methods for cancer and pain relief.
Dr. Mehta tells a personal story of his past that involved his father’s diagnosis of papillary thyroid cancer, and how it was the holistic and natural methods Dr. Mehta recommended that gave him extended life. Vitamin C Therapy, consuming organic wheatgrass daily, and daily deep breathing techniques to increase oxygen levels all contributed to him living 3 years longer than his prognosis. After massive shrinkage of the tumors during those 3 years; his father was convinced by an Ocologist to undergo chemotherapy in hopes that it would completely eradicate the cancer from his body. The chemotherapy caused cardio toxicity and unfortunately ultimately lead to Dr. Mehta’s father passing away.
di Girolamo suggests that viewers watch Research Rundown Episode 16: The Ketogenic Diet and Hyperbaric Oxygen Therapy Prolong Survival in Mice with Systemic Metastatic Cancer. This is a popular Research Rundown where our host, Ed di Girolamo, analyzes a study led by researcher, Dominic D’Agostino. The benefit of combining ketogenic diet with Hyperbaric Oxygen Therapy (HBOT) for metastatic cancer treatment is some very exciting research in the world of HBOT, cancer research, and fasting! This particular research and Dominic’s involvement to help prove that cancer can be eliminated (and maybe even cured) by combining a heavy ketogenic diet and Hyperbaric Oxygen Therapy is further discussed in this HBOT News Conversations episode with Dr. Mehta.
*Pease consult your doctor to see if fasting is right for you.
Guest

Dr. Hemal Mehta
Subscribe Now, It’s Free!
Recent HBOT News
Clinical Trial – Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplantation
By doing this study, researchers hope to learn the following:
– The safety of hyperbaric oxygen administration in the setting of the autologous
transplant
– The effects of hyperbaric oxygen administration on neutrophil count recovery and
engraftment
Evaluation of hyperbaric oxygen therapy for chronic wounds.
Abstract: Treating chronic wounds is challenging. Despite standard wound care, some chronic wounds fail to heal. Therefore, hyperbaric oxygen therapy (HBOT) was developed as an adjunct to standard wound care. To evaluate the efficacy of HBOT for treating chronic...
Clinical Trial – Hyperbaric Oxygen Therapy for Mild Cognitive Impairment
Dementia is a very frequent cognitive disorder among elderly individuals. Its prevalence is
about 15-20% of the population over the age of 65. The most common forms of dementia among
the elderly demented patients are Alzheimer’s disease (AD) (prevalence of 70%) and Vascular
dementia (VD) (prevalence of about 30-40%).There is also a high rate (about 40%) of
coexisting of AD and VD among the dementia patients, defined as mixed dementia.
Mild Cognitive Impairment (MCI) is a pre-dementia phase of cognitive decline. It is also
considered as a prodromal phase of both VD and AD. Its basic clinical features include:
cognitive concern, reflecting a change in cognition, reported by the patient or informant
(i.e., historical or observed evidence of decline over time), with objective evidence of
impairment in one or more cognitive domains (i.e., by formal cognitive testing), as well as
preservation of independence in functional abilities and not being demented (i.e., no
significant impairment social or occupational functioning).
Hyperbaric oxygen therapy (HBOT) has been investigated for treatment of numerous diseases for
more than 300 years. The principal effect of HBOT is increasing the solubility of oxygen in
plasma to a level sufficient to support tissues with minimal oxygen supply carried on by
hemoglobin. Clinical studies published this year present convincing evidence that hyperbaric
oxygen therapy (HBOT) can be the coveted neurotherapeutic method for brain repair. Thus, it
seems that HBOT might be an efficient and clinically feasible method capable of increasing
tissue/cellular oxygenation and effectively evoking neuroplasticity in the chronically
vascular-lesioned areas during the post microvascular lesion phase.
This is a prospective, randomized, control crossed over, study evaluating the effect of HBOT
in patients suffering from Mild Cognitive Impairment and Vascular Subcortical Ischemia.
